VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VOR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VORVor Biopharma Inc.
$18.97$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
VOR logo

Vor Biopharma Inc.

VOR
NASDAQ · Immunology Biotech
$18.97
At close - Nov 16, 4:00 PM EST - USD
Market Cap$1.13B
P/E0.8x
52W High$26.00
Volume763.21K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Negative Equity and Cash Burn Threaten Vor's Viability

Vor Biopharma's pre-revenue status and escalating R&D spending, which spiked to $261.5M in 2025Q2, have driven cumulative net losses exceeding $3.5B over ten quarters, eroding equity to -$200.2M by 2026Q2.

GrowthMixed
ProfitabilityNegative
ValuationAttractive
TechnicalsMixed
Explore valuation models
MARKET ACTION

VOR price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

2/12 Beats

EPS beat 2 of last 12 quarters

02

Valuation risk

-97% Peers

P/E is 97% below peer median

03

Market leadership

RS 88 · Leader

High momentum (Outperforming 88% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Jan 30

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
VOR+62.97%
S&P 500 (^GSPC)+8.31%
1-Year Return
VOR+89.32%
S&P 500 (^GSPC)+11.16%
3-Year Return
VOR-46.11%
S&P 500 (^GSPC)+63.61%
5-Year Return
VOR-94.52%
S&P 500 (^GSPC)+58.85%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$696M-495.3% YoY
Free cash flow FY25
-$144M-43.8% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-64.4%
ROE (FY25)-
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate2/12 (17%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 30, 2026
-$1.45-34.3%
vs -$1.08
—
vs —
Q3 2026
Aug 11, 2026
-$1.16-68.1%
vs -$0.69
—
vs —
Q2 2026
May 13, 2026
-$0.73+2.7%
vs -$0.75
—
vs —
Q2 2026
Mar 30, 2026
$44.50+4003.5%
vs -$1.14
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·4d ago
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise

RemeGen's expertise and next generation engineering expand Vor Bio's leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high potency and extended half-life for potentially best-in-class efficacy and dosing RC298 is in IND-enabling development, with an initial regulatory filing anticipated in the first half of 2027 in China Cash runway reaffirmed into early 2029 BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced an amendment to its existing agreement with RemeGen Co., Ltd (HKEX: 9995, SHA: 688331) to add RC298, a next-generation dual BAFF/APRIL inhibitor, to Vor Bio's exclusive license for development and commercialization outside of Greater China. RC298 is an engineered TACI-Fc fusion protein designed to inhibit both BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), two key regulators of pathogenic B cell and plasma cell biology.

GlobeNewsWire·6d ago
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference

BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London, United Kingdom. Presentation: Tuesday, November 17, 2026 at 10:30am – 10:55 am GMT A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com.

GlobeNewsWire·Nov 4, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 24,650 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 5,300 shares of Vor Bio's common stock to 2 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

GlobeNewsWire·Oct 30, 2026
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27

Filtered for Vor Biopharma Inc.More Headlines
04

Compare before deciding

Benchmark VOR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Vor Biopharma Inc. (VOR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
VOR logoVORVor Biopharma Inc.Current
$18.97$1.13B0.84————
BEAM logoBEAMBeam Therapeutics Inc.
$20.94$2.15B-20.47120.01%-73.04%-9.69%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.37$3.89B-8.56-89.97%-1812.07%-25.59%—
EDIT logoEDITEditas Medicine, Inc.
$1.87$286.97M-3.9825.39%-144.95%-130.43%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.86$1.11B-3.2416.92%-805.75%-64.73%—
FATE logoFATEFate Therapeutics, Inc.
$1.14$132.88M-1.13-51.24%-2619.64%-73.92%—

Compare VOR vs Peers

Vor Biopharma Inc. (VOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BEAM

Most directly comparable listed peer for VOR.

Scale Benchmark

vs ILMN

Larger-name benchmark to compare VOR against a more recognizable public peer.

Peer Set

Compare Top 5

vs BEAM, CRSP, EDIT, NTLA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

VOR SEC Filings & Documents

Vor Biopharma Inc. (VOR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 7, 2026·SEC

Material company update

Jun 12, 2026·SEC

Material company update

Jun 8, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 11, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when VOR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

VOR Frequently Asked Questions

Vor Biopharma Inc. (VOR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is VOR profitable?

Yes. Vor Biopharma Inc. (VOR) earned $1.35B in net income over the trailing twelve months.

Dividend & Returns
What is Vor Biopharma Inc.'s free cash flow?

Vor Biopharma Inc. (VOR) had negative free cash flow of $120.0M over the trailing twelve months.

What if you invested $1,000 in VOR back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →